Lilly and Novo Nordisk’s battle for weight loss drugs reaches pharmacies
Weight loss drug Zepbound gains ground in the US against Novo Nordisk’s Wegovy. Lilly has about 40% market share in the U.S., reaching 130,000 prescriptions in the week ending July 19, compared to Wegovy’s 200,000, according to IQVIA data.
ПОПУЛЯРНЫЕ ПОСТЫ
Poland prepares for peaking floods
Сентябрь 20, 2024
Italy evacuates thousands as Boris hits the north
Сентябрь 20, 2024
China and the US race to tame nuclear fusion for clean energy
Сентябрь 20, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ